000 | 03407nam a22006255i 4500 | ||
---|---|---|---|
001 | 978-3-030-86076-9 | ||
003 | DE-He213 | ||
005 | 20250526092116.0 | ||
007 | cr nn 008mamaa | ||
008 | 220131s2022 sz | s |||| 0|eng d | ||
020 |
_a9783030860769 _9978-3-030-86076-9 |
||
024 | 7 |
_a10.1007/978-3-030-86076-9 _2doi |
|
050 | 4 | _aRC1-1245 | |
050 | 4 | _aRC1-1245 | |
072 | 7 |
_aMJ _2bicssc |
|
072 | 7 |
_aMJ _2bicssc |
|
072 | 7 |
_aMED045000 _2bisacsh |
|
072 | 7 |
_aMJ _2thema |
|
072 | 7 |
_aMJ _2thema |
|
082 | 0 | 4 |
_a616 _223 |
082 | 0 | 4 |
_a616 _223 |
245 | 1 | 0 |
_aPrevention and Treatment of Atherosclerosis _h[electronic resource] : _bImproving State-of-the-Art Management and Search for Novel Targets / _cedited by Arnold von Eckardstein, Christoph J. Binder. |
250 | _a1st ed. 2022. | ||
264 | 1 |
_aCham : _bSpringer International Publishing : _bImprint: Springer, _c2022. |
|
300 |
_aX, 538 p. 40 illus., 37 illus. in color. _bonline resource. |
||
336 |
_atext _btxt _2rdacontent |
||
337 |
_acomputer _bc _2rdamedia |
||
338 |
_aonline resource _bcr _2rdacarrier |
||
347 |
_atext file _bPDF _2rda |
||
490 | 1 |
_aHandbook of Experimental Pharmacology, _x1865-0325 ; _v270 |
|
505 | 0 | _aDiet, Life Style, Smoking -- Blood Pressure Lowering -- Glycemic Control in Diabetes -- LDL-Cholesterol Lowering -- Antithrombotic Therapy (Platelet Inhibition, Anti-coagulation) -- Triglyceride Rich Lipoproteins -- HDL -- Lipoprotein(a) -- Obesity, Non-alcoholic Fatty Liver Disease, and Metabolic Syndrome -- Nutraceuticals / Functional Food -- Adipose Tissue (WAT, BAT) -- Microbiota and Cardiometabolic Disease -- SMCs, Matrix -- Immune Modulation -- NETs and Neutrophils -- Genomic Strategies Towards Identification of Novel Therapeutic Targets -- Non Coding RNAs -- Metabolomics, Lipidomics -- Epigenomics. | |
506 | 0 | _aOpen Access | |
520 | _aThis open access book is supported by the European Atherosclerosis Society Association (EAS). This follow-up edition of the well-received Handbook volume 'Atherosclerosis: Diet and Drugs' reflects the state-of-the-art and most recent developments in atherosclerosis research. Outstanding international experts give a comprehensive overview of the field covering topics, such as improving the treatment focusing on established targets, novel drug developments addressing pre-defined targets, hypothesis-based and hypothesis-free approaches to unravel novel targets. . | ||
650 | 0 | _aInternal medicine. | |
650 | 0 | _aPharmacology. | |
650 | 0 | _aDiseases. | |
650 | 1 | 4 | _aInternal Medicine. |
650 | 2 | 4 | _aPharmacology. |
650 | 2 | 4 | _aInternal Medicine. |
650 | 2 | 4 | _aDiseases. |
700 | 1 |
_avon Eckardstein, Arnold. _eeditor. _4edt _4http://id.loc.gov/vocabulary/relators/edt |
|
700 | 1 |
_aBinder, Christoph J. _eeditor. _4edt _4http://id.loc.gov/vocabulary/relators/edt |
|
710 | 2 | _aSpringerLink (Online service) | |
773 | 0 | _tSpringer Nature eBook | |
776 | 0 | 8 |
_iPrinted edition: _z9783030860752 |
776 | 0 | 8 |
_iPrinted edition: _z9783030860776 |
776 | 0 | 8 |
_iPrinted edition: _z9783030860783 |
830 | 0 |
_aHandbook of Experimental Pharmacology, _x1865-0325 ; _v270 |
|
856 | 4 | 0 | _uhttps://doi.org/10.1007/978-3-030-86076-9 |
912 | _aZDB-2-SBL | ||
912 | _aZDB-2-SXB | ||
912 | _aZDB-2-SOB | ||
999 |
_c74 _d74 |